BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dear Doctor Letter (Rote-Hand-Brief) on medicinal products containing sonidegib (Odomzo® capsules): important information for minimising the teratogenic risk

Active substance: sonidegib

Medicinal products containing sonidegib are embryotoxic and/or teratogenic and can cause embryo-foetal death or severe birth defects when administered to pregnant women; therefore, Odomzo® must not be taken during pregnancy.
Active substance: Sonidegib

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 133KB, File does not meet accessibility standards